retatrutide nonalcoholic fatty liver disease nash trial Fatty Liver Disease and Fibrosis (NASH) Clinical Trial A pivotal year for NAFLD

The interesting feature of this stack is the mismatch in cadence: Retatrutides long-acting profile contrasts with AOD-9604s short half-life

The first experiments demonstrating effects of peripheral GLP-1 in humans were published by Flint et al

Some GLP-1 users report muscle pain on tirzepatide or general body aches that make exercise feel daunting

Eur J Pharmacol 991: 177305

J.sbergA.HartmannA.MidtvedtK.KhiabaniH

Based on experience with the broader GLP-1 receptor agonist class (including semaglutide and tirzepatide), the following additional risks are relevant and should be discussed with a healthcare professional: Acute pancreatitis : Severe, persistent abdominal pain particularly pain radiating to the back may be a sign of pancreatitis and requires urgent medical assessment